Please assess the completion status of the following clinical trial:

Trial Title: Intravitreal Triamcinolone for Clinically Significant Diabetic Macular Oedema That Persists After Laser Treatment (TDMO)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2/PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Clinically significant diabetic macular oedema involving the fovea in one or both eyes (phakic and/or pseudophakic) which persists at least 3 months after adequate macular photocoagulation.~* best corrected visual acuity in the affected eye(s) 6/9 or worse~Exclusion Criteria:~* Glaucoma which is uncontrolled or is controlled but with glaucomatous visual field defects~* Loss of vision due to other causes (e.g. age related macular degeneration, myopic macular degeneration)~* Significant macular ischemia (FFA)~* No useful vision in fellow eye~* Known allergies to triamcinolone acetate or steroids~* Patient is already under systemic treatment with \> 5mg prednisolone (or equivalent) daily.~* Intercurrent severe disease such as septicaemia~* Any condition which would affect follow-up or photographic documentation (e.g. geographical, psycho-social, media opacities)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).